The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.

Researchers found that cancer incidence is on the decline for Black patients and rising for White patients, but mortality is on the decline for both groups.

A phytochemical-rich food supplement can slow PSA progression in patients with prostate cancer, and adding a probiotic can enhance this effect.

The AlloHeme test can be used to predict relapse after allogeneic HCT in patients with AML or MDS, data suggest.

Fixed-duration acalabrutinib and venetoclax, with or without obinutuzumab, may improve outcomes over chemoimmunotherapy in patients with previously untreated CLL.

Further assessment is needed to understand if these treatment recommendations were eventually adopted and if adoption leads to better outcomes,” researchers wrote.

Although there was a significant decline in the age-adjusted incidence-based mortality rate from 2006 to 2020, our study did not show a significant improvement in survival outcomes,” the researchers ...

(HealthDay News) — Overdiagnosis of thyroid cancer remains a persistent problem in the United States, researchers reported in The Lancet Diabetes & Endocrinology.

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

Consuming a lower-fat diet and taking a fish oil supplement daily reduced the Ki-67 index in patients with prostate cancer on active surveillance.

Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with mHSPC may not receive it.

The FDA has approved the biologics license applications for Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, respectively.